{"component": "definition", "props": {"groups": [{"snippet": "means Elan Corp and its Affiliates.", "samples": [{"hash": "kFlcM2BA0Sp", "uri": "/contracts/kFlcM2BA0Sp#elan", "label": "Termination and Assignment Agreement", "score": 31.3408622742, "published": true}, {"hash": "5dN904aQO8m", "uri": "/contracts/5dN904aQO8m#elan", "label": "Termination Agreement", "score": 29.3408622742, "published": true}, {"hash": "8o9TMNkf1wN", "uri": "/contracts/8o9TMNkf1wN#elan", "label": "Termination Agreement (Zealand Pharma a/S)", "score": 28.5099239349, "published": true}], "snippet_links": [{"key": "elan-corp", "type": "definition", "offset": [6, 15]}], "size": 32, "hash": "2127d3105ffcc879102e5b5a48e90703", "id": 1}, {"snippet": "means EPIL and Affiliates and subsidiaries of Elan Corporation, Plc. within the division of Elan Corporation, Plc. carrying on business as Elan Pharmaceutical Technologies but shall not include Affiliates and subsidiaries (present or future) of Elan Corporation Plc within the division of Elan Corporation, Plc carrying on business as Elan Pharmaceuticals which incorporates, inter alia, Targon Corporation, Athena Neurosciences, Inc., Elan Pharmaceuticals, Inc., Elan Diagnostics, Carnrick Laboratories, and Elan Europe Limited.", "samples": [{"hash": "iipm6MFp7EC", "uri": "/contracts/iipm6MFp7EC#elan", "label": "License Agreement (Sheffield Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "eAQIbEVc4Se", "uri": "/contracts/eAQIbEVc4Se#elan", "label": "License Agreement (Sheffield Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "6aNaYGajGxe", "uri": "/contracts/6aNaYGajGxe#elan", "label": "License Agreement (Sheffield Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "affiliates-and-subsidiaries", "type": "definition", "offset": [15, 42]}, {"key": "the-division", "type": "clause", "offset": [76, 88]}, {"key": "carrying-on-business", "type": "clause", "offset": [115, 135]}, {"key": "inter-alia", "type": "clause", "offset": [376, 386]}], "size": 12, "hash": "595f1fcc09eb5719e08694914f7bd279", "id": 2}, {"snippet": "means Elan Corporation, plc (Elan will be acting through its division Elan Pharmaceutical Technologies);", "samples": [{"hash": "e82qMng58h3", "uri": "/contracts/e82qMng58h3#elan", "label": "License Agreement (Endorex Corp)", "score": 18.0, "published": true}, {"hash": "6A6j9ppMvd9", "uri": "/contracts/6A6j9ppMvd9#elan", "label": "License Agreement (Endorex Corp)", "score": 18.0, "published": true}, {"hash": "5FJkn6hTacU", "uri": "/contracts/5FJkn6hTacU#elan", "label": "License Agreement (Endorex Corp)", "score": 18.0, "published": true}], "snippet_links": [], "size": 11, "hash": "745f1e515fc5c309c2717376c3e28e2a", "id": 3}, {"snippet": "means Elan Pharma International Limited, a company incorporated in Ireland, and its affiliates.", "samples": [{"hash": "aaxCzfq8El6", "uri": "/contracts/aaxCzfq8El6#elan", "label": "License Agreement (Jazz Pharmaceuticals Inc)", "score": 21.3422317505, "published": true}, {"hash": "6WbAiOkc8RC", "uri": "/contracts/6WbAiOkc8RC#elan", "label": "License Agreement (Jazz Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "5P1G6awFJTo", "uri": "/contracts/5P1G6awFJTo#elan", "label": "License Agreement (Jazz Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "international-limited", "type": "definition", "offset": [18, 39]}], "size": 10, "hash": "98b66b24bcbe4d74f9e506440b6a9053", "id": 4}, {"snippet": "means Elan, plc and EPIL.", "samples": [{"hash": "jezBiZ7OaMS", "uri": "/contracts/jezBiZ7OaMS#elan", "label": "Subscription, Joint Development and Operating Agreement (Ribozyme Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "9qKhxiqvVch", "uri": "/contracts/9qKhxiqvVch#elan", "label": "Subscription, Joint Development and Operating Agreement (Athersys Inc /Oh)", "score": 18.0, "published": true}, {"hash": "6Tk2QI76Hrx", "uri": "/contracts/6Tk2QI76Hrx#elan", "label": "Subscription, Joint Development and Operating Agreement (Ribozyme Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [], "size": 9, "hash": "58da1f95c3782cdcb9e0ea95fe90b684", "id": 5}, {"snippet": "means Elan, plc and EPIL, and their respective successors and permitted assigns.", "samples": [{"hash": "kYgdwSk3fcl", "uri": "/contracts/kYgdwSk3fcl#elan", "label": "License Agreement (Ribozyme Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "juZh0SFCFET", "uri": "/contracts/juZh0SFCFET#elan", "label": "License Agreement (Ribozyme Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "gPFU0LVOpYY", "uri": "/contracts/gPFU0LVOpYY#elan", "label": "License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "respective-successors-and-permitted-assigns", "type": "clause", "offset": [36, 79]}], "size": 8, "hash": "977ef7d8dfd90553e48297288f58fadc", "id": 6}, {"snippet": "means Elan Corporation plc, a public limited company incorporated under the laws of Ireland (registered no. 30356);", "samples": [{"hash": "3vuQzaSdhHD", "uri": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0001559053/f311895c-b024-4565-acdf-4348ec4ec549.pdf", "label": "Proxy", "score": 22.4306439105, "published": false}, {"hash": "35P1txrk8sJ", "uri": "https://ir.prothena.com/static-files/d0f946df-e65f-457a-aca1-2f406907e86d", "label": "Amendment", "score": 13.9637231827, "published": false}, {"hash": "5Mhulv1V7uu", "uri": "https://www.sec.gov/Archives/edgar/data/1559053/000119312513133056/d507548dex31.htm", "label": "Articles of Association (Prothena Corp PLC)", "score": 10.2388772964, "published": false}], "snippet_links": [{"key": "limited-company", "type": "clause", "offset": [37, 52]}, {"key": "the-laws", "type": "definition", "offset": [72, 80]}], "size": 6, "hash": "11aaf5749f9ced2e5b6286fd58b41cc2", "id": 7}, {"snippet": "means Elan Corporation, plc, a public limited company organized and existing under the laws of Ireland.", "samples": [{"hash": "8ZhIH85h0FY", "uri": "https://www.sec.gov/Archives/edgar/data/886163/000093639299000360/3.txt", "label": "Securities Purchase Agreement (Ligand Pharmaceuticals Inc)", "score": 6.0, "published": false}, {"hash": "9CS6AAkGB2V", "uri": "https://www.sec.gov/Archives/edgar/data/886163/000093639299000360/2.txt", "label": "Securities Purchase Agreement (Ligand Pharmaceuticals Inc)", "score": 6.0, "published": false}, {"hash": "f519OijRzMb", "uri": "https://www.sec.gov/Archives/edgar/data/886163/000088616399000004/8.txt", "label": "Securities Purchase Agreement (Ligand Pharmaceuticals Inc)", "score": 6.0, "published": false}], "snippet_links": [{"key": "organized-and-existing", "type": "clause", "offset": [54, 76]}, {"key": "the-laws", "type": "definition", "offset": [83, 91]}], "size": 6, "hash": "df905742b4b2c0e6a5b173e6b58bed9a", "id": 8}, {"snippet": "means Elan Pharmaceutical Technologies, a division of Elan Corporation, plc, a public limited company incorporated under the laws of Ireland, its, successors and permitted assigns;", "samples": [{"hash": "9VRog5yI0im", "uri": "/contracts/9VRog5yI0im#elan", "label": "License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "6nkjUkijGZt", "uri": "/contracts/6nkjUkijGZt#elan", "label": "License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "6KhhfzXliz4", "uri": "https://ir.ionispharma.com/static-files/4d8d833c-c715-4534-8d51-92bd3efa7380", "label": "Amendment", "score": 13.6707735062, "published": false}], "snippet_links": [{"key": "limited-company", "type": "clause", "offset": [86, 101]}, {"key": "the-laws", "type": "definition", "offset": [121, 129]}, {"key": "successors-and-permitted-assigns", "type": "clause", "offset": [147, 179]}], "size": 5, "hash": "ddd27afdea135e770283a92933737095", "id": 9}, {"snippet": "means Elan Pharmaceuticals, Inc.", "samples": [{"hash": "8zf9vUYBgbW", "uri": "/contracts/8zf9vUYBgbW#elan", "label": "License Agreement (Hana Biosciences Inc)", "score": 19.0, "published": true}, {"hash": "8DmgRbWbcPs", "uri": "/contracts/8DmgRbWbcPs#elan", "label": "Development Agreement (Enzon Pharmaceuticals  Inc)", "score": 18.0, "published": true}, {"hash": "dT0DvmjCJtK", "uri": "https://investor.enzon.com/static-files/21486f01-7347-4b54-8824-0b517ffb88c4", "label": "investor.enzon.com", "score": 6.5249829292, "published": false}], "snippet_links": [], "size": 5, "hash": "5ce0bc4c0dba63d763c8fb37d622ee09", "id": 10}], "next_curs": "ClESS2oVc35sYXdpbnNpZGVyY29udHJhY3Rzci0LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiINZWxhbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means Elan Corp and its Affiliates.", "title": "Elan", "size": 184, "id": "elan", "examples": ["At its option, Acorda may elect to take over the conduct of such proceedings from <strong>Elan</strong>.", "Nothing contained in this Agreement is intended or is to be construed to constitute <strong>Elan</strong> and Newco as partners, or <strong>Elan</strong> as an employee of Newco, or Newco as an employee of <strong>Elan</strong>.", "Any such tax required to be paid or withheld shall be an expense of and borne solely by <strong>Elan</strong>.", "The waiver and release are part of the consideration for issuance of the Notes, the <strong>Elan</strong> Note Guarantee and the Subsidiary Note Guarantees.", "Newco shall not sell or otherwise dispose of any Product under the <strong>Elan</strong> Trademarks that fails to comply with the quality standards and specifications referred to in this Clause 3.2, as determined by <strong>Elan</strong>.", "In remitting such royalty payments such Designees(s) will abide by the terms of this Article 5.9. No such direct payments will be made by any Acorda Designee unless Acorda and <strong>Elan</strong> have beforehand agreed that such direct royalty payment and such direct payments shall not adversely affect the withholding liability of <strong>Elan</strong> compared to the payments made by Acorda to <strong>Elan</strong>.", "<strong>Elan</strong> or Carrier, as agent for <strong>Elan</strong>, may post signage on the vaults of the ATMs indicating ownership of the Currency.", "Each of <strong>Elan</strong> and Acorda hereby acknowledges and agrees that the licences previously granted to <strong>Elan</strong> by Rush and the licenses granted to Acorda by Rush pursuant to the Rush/Acorda License do not constitute <strong>Elan</strong> Patent Rights or <strong>Elan</strong> Know-How for the purposes of this Agreement.", "In the event that there is a deficiency in the CMC Section attributable to negligence by <strong>Elan</strong> in the activities conducted by <strong>Elan</strong>, then <strong>Elan</strong> shall be responsible for correcting such deficiency, at <strong>Elan</strong>\u2019s expense, and shall use reasonable efforts to do so as soon as practicable.", "Neither Party shall acknowledge to a Third Party or to any other person the validity of the patent rights of such a Third Party, the invalidity of the <strong>Elan</strong> Patent Rights or the Acorda Patent Rights and shall not compromise or settle any claim or proceedings relating thereto without the written consent of the other Party, such consent not to be unreasonably withheld or delayed."], "related": [["novartis", "Novartis", "Novartis"], ["merck", "Merck", "Merck"], ["bms", "BMS", "BMS"], ["nps", "NPS", "NPS"], ["isis", "ISIS", "ISIS"]], "related_snippets": [], "updated": "2025-07-10T04:27:38+00:00"}, "json": true, "cursor": ""}}